IL13 and asthma: An anti-IL-13 antibody, lebrikizumab, has been shown to improve FEV1 (forced expiratory volume measured during the first second) and reduce IL-13-related biomarkers in clinical trials, but has not consistently shown reduction of asthma exacerbations [3, 4].